Citation: Db. Sokol et Gr. Hudes, CISPLATIN-BASED CHEMOTHERAPY FOR TESTICULAR CANCER IN A PATIENT WITH SPINAL MUSCULAR-ATROPHY - A CASE-REPORT, American journal of clinical oncology, 21(4), 1998, pp. 420-421
Authors:
RANGANATHAN S
DEXTER DW
BENETATOS CA
HUDES GR
Citation: S. Ranganathan et al., CLONING AND SEQUENCING OF HUMAN BETA(III)-TUBULIN CDNA - INDUCTION OFBETA(III) ISOTYPE IN HUMAN PROSTATE CARCINOMA-CELLS BY ACUTE EXPOSURETO ANTIMICROTUBULE AGENTS, Biochimica et biophysica acta, N. Gene structure and expression, 1395(2), 1998, pp. 237-245
Authors:
RANGANATHAN S
BENETATOS CA
COLARUSSO PJ
DEXTER DW
HUDES GR
Citation: S. Ranganathan et al., ALTERED BETA-TUBULIN ISOTYPE EXPRESSION IN PACLITAXEL-RESISTANT HUMANPROSTATE CARCINOMA-CELLS, British Journal of Cancer, 77(4), 1998, pp. 562-566
Authors:
HUDES GR
NATHAN F
KHATER C
HAAS N
CORNFIELD M
GIANTONIO B
GREENBERG R
GOMELLA L
LITWIN S
ROSS E
ROETHKE S
MCALEER C
Citation: Gr. Hudes et al., PHASE-II TRIAL OF 96-HOUR PACLITAXEL PLUS ORAL ESTRAMUSTINE PHOSPHATEIN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER, Journal of clinical oncology, 15(9), 1997, pp. 3156-3163
Authors:
RANGANATHAN S
SALAZAR H
BENETATOS CA
HUDES GR
Citation: S. Ranganathan et al., IMMUNOHISTOCHEMICAL ANALYSIS OF BETA-TUBULIN ISOTYPES IN HUMAN PROSTATE CARCINOMA AND BENIGN PROSTATIC HYPERTROPHY, The Prostate, 30(4), 1997, pp. 263-268
Authors:
HAGEBOUTROS A
HUDES GR
GREENE F
LACRETA FP
BRENNAN J
ODWYER PJ
Citation: A. Hageboutros et al., PHASE-I TRIAL OF FLUOROURACIL MODULATION BY N-PHOSPHONACETYL-L-ASPARTATE AND 6-METHYLMERCAPTOPURINE RIBONUCLEOSIDE (MMPR), AND LEUCOVORIN IN PATIENTS WITH ADVANCED CANCER, Investigational new drugs, 15(2), 1997, pp. 139-145
Authors:
HAGEBOUTROS A
HUDES GR
BRENNAN J
GREEN F
HOFFMAN J
LACRETA FP
COLOFIORE J
MARTIN DS
OZOLS RF
ODWYER PJ
Citation: A. Hageboutros et al., PHASE-I TRIAL OF FLUOROURACIL MODULATION BY N-PHOSPHONACETYL-L-ASPARTATE AND 6-METHYLMERCAPTOPURINE RIBONUCLEOSIDE, Cancer chemotherapy and pharmacology, 37(3), 1996, pp. 229-234
Authors:
RANGANATHAN S
DEXTER DW
BENETATOS CA
CHAPMAN AE
TEW KD
HUDES GR
Citation: S. Ranganathan et al., INCREASE OF BETA(III)-TUBULIN AND BETA(IVA)-TUBULIN ISOTYPES IN HUMANPROSTATE CARCINOMA-CELLS AS A RESULT OF ESTRAMUSTINE RESISTANCE, Cancer research, 56(11), 1996, pp. 2584-2589
Authors:
HAGEBOUTROS A
ROGATKO A
NEWMAN EM
MCALEER C
BRENNAN J
LACRETA FP
HUDES GR
OZOLS RF
ODWYER PJ
Citation: A. Hageboutros et al., PHASE-I STUDY OF PHOSPHONACETYL-L-ASPARTATE, 5-FLUOROURACIL, AND LEUCOVORIN IN PATIENTS WITH ADVANCED CANCER, Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 205-212
Authors:
HUDES GR
KOSIEROWSKI R
GREENBERG R
RAMSEY HE
FOX SC
OZOLS RF
MCALEER CA
GIANTONIO BJ
Citation: Gr. Hudes et al., PHASE-II STUDY OF TOPOTECAN IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER, Investigational new drugs, 13(3), 1995, pp. 235-240
Authors:
HUDES GR
NATHAN FE
KHATER C
GREENBERG R
GOMELLA L
STERN C
MCALEER C
Citation: Gr. Hudes et al., PACLITAXEL PLUS ESTRAMUSTINE IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER, Seminars in oncology, 22(5), 1995, pp. 41-45
Authors:
HUDES GR
OBASAJU C
CHAPMAN A
GALLO J
MCALEER C
GREENBERG R
Citation: Gr. Hudes et al., PHASE-I STUDY OF PACLITAXEL AND ESTRAMUSTINE - PRELIMINARY ACTIVITY IN HORMONE-REFRACTORY PROSTATE-CANCER, Seminars in oncology, 22(3), 1995, pp. 6-11
Authors:
SMITH CD
ZILFOU JT
ZHANG XQ
HUDES GR
TEW KD
Citation: Cd. Smith et al., MODULATION OF P-GLYCOPROTEIN ACTIVITY BY ESTRAMUSTINE IS LIMITED BY BINDING TO PLASMA-PROTEINS, Cancer, 75(10), 1995, pp. 2597-2604
Authors:
SPEICHER LA
BARONE LR
CHAPMAN AE
HUDES GR
LAING N
SMITH CD
TEW KD
Citation: La. Speicher et al., P-GLYCOPROTEIN BINDING AND MODULATION OF THE MULTIDRUG-RESISTANT PHENOTYPE BY ESTRAMUSTINE, Journal of the National Cancer Institute, 86(9), 1994, pp. 688-694
Authors:
ROTH BJ
DREICER R
EINHORN LH
NEUBERG D
JOHNSON DH
SMITH JL
HUDES GR
SCHULTZ SM
LOEHRER PJ
Citation: Bj. Roth et al., SIGNIFICANT ACTIVITY OF PACLITAXEL IN ADVANCED TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM - A PHASE-II TRIAL OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP, Journal of clinical oncology, 12(11), 1994, pp. 2264-2270
Authors:
HAAS NB
LACRETA FP
WALCZAK J
HUDES GR
BRENNAN JM
OZOLS RF
ODWYER PJ
Citation: Nb. Haas et al., PHASE-I PHARMACOKINETIC STUDY OF TOPOTECAN BY 24-HOUR CONTINUOUS-INFUSION WEEKLY, Cancer research, 54(5), 1994, pp. 1220-1226